Application of insulin-like growth factor 1 receptor inhibitor BMS536924 in preparation of medicine for treating cystic hydatid disease
A BMS536924, receptor inhibitor technology, applied in drug combinations, pharmaceutical formulations, anti-infectives, etc., can solve the problems of unsatisfactory treatment effect, long-term use, and poor intestinal absorption of benzimidazoles
Inactive Publication Date: 2021-09-17
THE FIRST TEACHING HOSPITAL OF XINJIANG MEDICAL UNIVERCITY
View PDF6 Cites 0 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
[0006] The present invention provides an insulin-like growth factor 1 receptor inhibitor BMS536924 as an application in the preparation of a drug for treating cystic echinococcosis, which overcomes the above-mentioned deficiencies in the prior art, and can supplement and solve the problem that there is no insulin-like growth factor 1 receptor inhibitor at present. There are related reports about the body inhibitor BMS536924 as a drug for the treatment of cystic echinococcosis; at the same time, benzimidazoles have poor intestinal absorption, need to be taken for a long time, and are prone to drug resistance, which leads to unsatisfactory therapeutic effects
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0032] Example 1, the application of the insulin-like growth factor 1 receptor inhibitor BMS536924 as a drug for the preparation of cystic echinococcosis.
Embodiment 2
[0033] Example 2, as an optimization of the above example, also includes the combined use of albendazole, insulin-like growth factor 1 receptor inhibitor BMS536924 and albendazole.
Embodiment 3
[0034] Example 3, as an optimization of the above example, the mass ratio of insulin-like growth factor 1 receptor inhibitor BMS536924 to albendazole is 1 to 2:1. It can be specifically the mass ratio of the insulin-like growth factor 1 receptor inhibitor BMS536924 and albendazole sulfoxide in the in vitro test of Echinococcus granulosus and vesicles from 1 to 8:1, and the insulin-like growth factor 1 receptor inhibitor in the mouse in vivo test. The mass ratio of growth factor 1 receptor inhibitor BMS536924 and albendazole is 1 to 2:1.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
The invention relates to the technical field of medicines for treating the hydatid disease, and particularly relates to application of an insulin-like growth factor 1 receptor inhibitor BMS536924 in preparation of a medicine for treating the cystic hydatid disease. The invention discloses the application of the BMS536924 in preparation of the medicine for treating the cystic hydatid disease for the first time. In-vivo and in-vitro experimental data shows that the BMS536924 is an efficient medicine molecule for resisting to the hydatid disease; the insulin-like growth factor 1 receptor inhibitor BMS536924 has remarkable treatment effects on the cystic hydatid disease, and the treatment effects are superior to those of an albendazole metabolite, i.e., albendazole sulfoxide; the medicine effect of the BMS536924 and ABZSO combined use is better than those of single administration of the BMS536924 and the ABZSO; and meanwhile, compared with the dosage of the single albendazole sulfoxide, the dosage of the BMS536924 combined albendazole is reduced by 1 / 4 to 1 / 2, so that the dosage and the drug resistance are greatly reduced, and a very good treatment effect is achieved.
Description
technical field [0001] The invention relates to the technical field of echinococcosis drugs, and relates to the application of an insulin-like growth factor 1 receptor inhibitor BMS536924 as a drug for treating cystic echinococcosis. Background technique [0002] Cystic Echinococcosis (CE) is caused by Echinococcus granulosus ( Echinococcus granulosus, Eg ) is a serious zoonotic parasitic disease caused by parasitizing the human body. It is a global neglected disease. In 2010, the World Health Organization reported that the disease will once again become an important public health problem, and it is necessary to strengthen prevention and develop new treatments way. The initial infection of the intermediate host with cystic echinococcosis is through oral infective eggs, and the hexaconidia are hatched in the stomach of the intermediate host, pass through the intestinal wall, and parasitize mainly in the liver. Due to the difficulty of controlling the source of infection a...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More IPC IPC(8): A61K31/5377A61K31/4184A61P33/10
CPCA61K31/5377A61K31/4184A61P33/10A61K2300/00
Inventor 吕国栋林仁勇李锦田刘辉毕晓娟杨宁
Owner THE FIRST TEACHING HOSPITAL OF XINJIANG MEDICAL UNIVERCITY
PatSnap Eureka turns technology decisions into work you can execute. Powered by our Innovation Knowledge Graph, it runs expert workflows across engineering, life sciences, materials and intellectual property. Get your review-ready output in minutes.
